K

KeyMed Biosciences Inc
HKEX:2162

Watchlist Manager
KeyMed Biosciences Inc
HKEX:2162
Watchlist
Price: 39.55 HKD -0.88%
Market Cap: 10.9B HKD
Have any thoughts about
KeyMed Biosciences Inc?
Write Note

P/E
Price to Earnings

-13.9
Current
-33.6
Median
22.7
Industry
Higher than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-13.9
=
Market Cap
11.1B HKD
/
Net Income
-743.1m CNY
All Countries
Close
Earnings Growth
CN
K
KeyMed Biosciences Inc
HKEX:2162
Average P/E: 210.4
Negative Multiple: -13.9
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -179 646.3 N/A
US
Abbvie Inc
NYSE:ABBV
63
412%
US
Amgen Inc
NASDAQ:AMGN
34.9
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -248.8
42%
US
Gilead Sciences Inc
NASDAQ:GILD
903.4
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -475.6 N/A
AU
CSL Ltd
ASX:CSL
33.1
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.1 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -130 N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-12.8
2-Years Forward
P/E
-13.1
3-Years Forward
P/E
-33.2

See Also

Discover More